-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Melanoma is a common and potentially lethal malignancy, and patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing melanoma and lower melanoma-specific survival rates
.
The effect of CLL on melanoma recurrence in advanced melanoma is currently unknown
Melanoma is a common and potentially lethal malignancy, and patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing melanoma and lower melanoma-specific survival rates
Therefore, understanding and managing melanoma in this vulnerable population is more important than ever
Figure 1: Kaplan-Meier survival curves of (A) melanoma-specific survival (MSS) and (B) recurrence-free survival (RFS) of melanoma patients with CLL compared to those without CLL
.
The log-rank comparison of MSS and RFS in the CLL group compared with the non-CLL group was significantly worse in the CLL group ( p= 0.
Figure 1: Kaplan-Meier survival curves of (A) melanoma-specific survival (MSS) and (B) recurrence-free survival (RFS) of melanoma patients with CLL compared to those without CLL
A research team conducted a retrospective case-control study to examine the impact of CLL and its treatment on melanoma-specific survival and recurrence
Multivariate analysis found that CLL was associated with significantly lower melanoma-specific mortality (hazard ratio [HR] 2.
Reassuringly, melanoma treatment, particularly the use of immunotherapy, was similar between the groups, suggesting that disproportionate use of the new therapy did not confound survival outcomes
.
Despite these limitations, the lack of current data in the literature means that this study provides novel, valuable insights into the impact of CLL on melanoma outcomes
With new and effective treatments, CLL patients live longer, and the impact of a second malignancy on their survival is becoming increasingly important
.
The research team found that patients with CLL who developed melanoma had poor MSS, RFS and potential immunotherapy intolerance
MSS, RFS, and underlying immunotherapy intolerance were poor in CLL patients who developed melanoma
Original source:
Original source:Jobson, D ,McCormack, CJ ,Mar, V ,Tam, C ,Henderson, MA .
Jobson, D ,McCormack, CJ ,Mar, V ,Tam, C ,Henderson, MA .
Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study .
Br J Haematol .
2022 ; 00 : 1 – 6.
https : //doi.
org/10.
1111/bjh.
18090.
Jobson, D McCormack, CJ Mar, V Tam, C Henderson, MA Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study Br J Haematol 2022 00 1 6https://doi.
org/10.
1111/bjh.
18090.
Leave a comment here
